There is significant chatter in Washington D.C. that U.S. President Barack Obama could use his executive authority to regulate drug pricing, a “flash note” from Evercore ISI analyst Terry Haines says. But such an action is unlikely for three primary reasons, says the research note delivered to institutional investors earlier Wednesday. Hot D.C. rumor: Obama may issue an executive order on drug prices The high profile cause comes as Martin Shkreli famously raised the price of a life saving aids drug by 5,500% — and then seemed to thumb his nose at Congress when he was called to testify. On…
Drug Pricing Executive Action Is Unlikely: Evercore ISI
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Comments are closed.